Table 2.

Virologic Results by Treatment Group and Baseline Features

	(Sustained Virologic Response percent) [95% Confidence Interval]
	Peginterferon/ribavirin (N=55)	Peginterferon/placebo (N=57)	P-Value
Total	29/55 (53%) [40%, 66%]	12/57 (21%) [10%, 32%]	.0005
Genotype 1	21/45 (47%) [32%, 61%]	8/46 (17%) [6%, 28%]	.0027
2 – 6	8/10 (80%) [55%, 100%]	4/11 (36%) [8%, 65%]	.0563*
Female	15/28 (54%) [35%, 72%]	8/23 (35%) [15%, 54%]	.1797
Male	14/27 (52%) [33%, 71%]	4/34 (12%) [1%, 23%]	.0007
Age <=11 years	15/30 (50%) [32%, 68%]	7/29 (24%) [9%, 40%]	.0400
>=12 years	14/25 (56%) [37%, 75%]	5/28 (18%) [4%, 32%]	.0038
White	22/43 (51%) [36%, 66%]	8/40 (20%) [8%, 32%]	.00031
Non-White	7/12 (58%) [30%, 86%]	4/17 (24%) [3%, 44%]	.0651*
ALT Normal	16/23 (70%) [51%, 88%]	6/20 (30%) [10%, 50%]	0.0096
> ULN	13/32 (41%) [24%, 58%]	6/37 (16%) [4%, 28%]	0.0246
HCV RNA < 600,000 IU/ml	16/23 (70%)	10/13 (78%)	p = 0.73
HCV RNA ≥ 600,000 IU/ml	16/32 (50%)	5/46 (11%)	p = 0.0002
Inflammation (Histology Activity Index)
Minimal (1–3)	10/23 (43%) [23%, 64%]	5/24 (21%) [5%, 37%]	0.0959
Mild-Marked (4–12)	18/31 (58%) [41%, 75%]	6/30 (20%) [6%, 34%]	0.0023
Fibrosis (Ishak stage)
None	3/7 (43%) [6%, 80%]	3/8 (38%) [4%, 71%]	0.8327
Stage 1–6	25/47 (53%) [39%, 67%]	8/48 (17%) [6%, 27%]	0.0003
Steatosis
Present	9/25 (36%) [17%, 55%]	1/21 (5%) [0%, 14%]	0.0105
Absent	19/29 (66%) [48%, 83%]	10/33 (30%) [15%, 46%]	0.0056